\
&
Contact us
\
&
Contact us
Published on | 10 months ago
Programmes EICThe European Innovation Council (EIC) selected 68 companies for funding, combining grants and equity, following the first in 2024 EIC Accelerator cut-off in March.
The companies were selected in a highly competitive process. From a total of 969 companies that submitted a full proposal, 347 companies were interviewed by juries of experienced investors and entrepreneurs. The jury then selected the 68 best companies to receive funding. The selected companies have a geographical spread spanning 17 countries. Together, the selected companies will receive an estimated €411 million in funding, of which up to €165 million in grants and an estimated €245 million in equity.
Among the selected companies is Pharrowtech, based in Leuven (https://pharrowtech.com/). Pharrowtech spun out of IMEC and designs and develops mmWave radio frequency technology for next-generation wireless applications.
More information in the European Innovation Council's news article.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
